Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00703534 · ClinicalTrials.gov registry record · Phase 2
Validation of Patient-reported Outcomes Measures for the Assessment of Gastroesophageal Reflux Disease (GERD) Symptoms
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 478
- Enrollment target
NCT00703534 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 478 participants.
The verdict
NCT00703534, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 478 participants
- Enrollment target
Study Summary
This research study is being done to gather information about how to do further clinical studies using AZD3355 as an add-on treatment to proton pump inhibitors (PPI).
Interventions
- DRUG Placebo
- DRUG AZD3355
- DRUG Gelusil®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 478 participants |
| Start Date | 2008-05 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00703534
The ClinicalTrials.gov registry entry for NCT00703534 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 478 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00703534 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00703534 about?
NCT00703534 is a clinical study titled "Validation of Patient-reported Outcomes Measures for the Assessment of Gastroesophageal Reflux Disease (GERD) Symptoms". This research study is being done to gather information about how to do further clinical studies using AZD3355 as an add-on treatment to proton pump inhibitors (PPI).
What is the current status of trial NCT00703534?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 478 participants. The study started on 2008-05. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00703534?
The interventions under investigation include: Placebo (DRUG), AZD3355 (DRUG), Gelusil® (DRUG).
Who is sponsoring clinical trial NCT00703534?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.